APASL 2026 Day 1 — What’s shaping hepatology right now?
From HEV insights to HBV biomarkers and AI-driven fibrosis prediction — key discussions are already setting the tone for clinical practice.
We’ve curated the most relevant highlights so you don’t miss what truly matters.
👉 Explore full updates on GastroAGI
#GastroAGI #APASL2026 #Hepatology #LiverDisease #HBV #HEV #MASLD #HCC #MedicalEducation #GIUpdates #MedEd #ClinicalInsights
🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?
⚠️ Promising data, but guidelines still need phase III confirmation
#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd
Nutrition is central in cirrhosis care. Malnutrition, sarcopenia, and frailty worsen transplant outcomes.
Early assessment, adequate calories, and high-quality protein prehabilitation preserve muscle and resilience. The waitlist is a window to intervene.
#Cirrhosis #Hepatology #TransplantMedicine #NutritionInCirrhosis #Sarcopenia #MedicalEducation #EvidenceBasedMedicine #GastroAGI
GastroAGI is an AI-powered knowledge platform for gastroenterology & hepatology—built for clinicians, trainees, and researchers.
Evidence-first answers from journals, guidelines, and conferences. No noise. No hallucinations. Just clarity.
#GastroAGI #Gastroenterology #Hepatology #MedicalAI #EvidenceBasedMedicine #MedEd #ClinicalPractice #GIResearch
COBALT Trial (PBC): Despite early termination, adjusted analyses + real-world external controls showed obeticholic acid (OCA) reduces major liver events.
EC (External Control) analysis: 60% risk reduction in the risk of adverse clinical outcomes like death, liver transplantation, or hepatic decompensation.(HR 0.39).
Well-tolerated; pruritus most common.
Highlights power of hybrid RCT + real-world evidence.